Auxly Cannabis Group Inc. operates in the Canadian cannabis market, focusing on developing and distributing consumer-packaged cannabis products. The company boasts strong gross (52.1%) and EBITDA margins (21.6%), indicating efficient operations. However, its return on equity (4.1%) and return on assets (2.8%) are relatively low, raising concerns about profitability. While the current (2.35) and quick ratios (1.46) suggest solid liquidity, the stock's recent decline of 0.90% may reflect market apprehension despite its healthy margins. Overall, Auxly presents a mixed financial picture with strengths in margins but weaknesses in returns.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Strong revenue growth of 18.8% YoY indicates solid business momentum.
Operating margin increased by 2.6pp, reflecting better cost management.
Strong gross margin of 52.9% reflects healthy unit economics.
Operating cash flow surged 63.0% YoY, indicating strong cash generation capability.
Excellent operating cash flow margin of 21.4% indicates high-quality earnings.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)